People using Wegovy, Mounjaro and other GLP-1 medicines have been told to act quickly if vision changes occur. South Korea’s Ministry of Food and Drug Safety advised patients to stop treatment and seek immediate medical care when they experience sudden, painless loss of vision or other visual problems in one eye.
The warning follows a US Food and Drug Administration decision to require stronger wording in the labels for GLP-1 medicines, including Wegovy, Ozempic, Mounjaro and Zepbound. The added information concerns non-arteritic anterior ischemic optic neuropathy, or NAION, a condition linked to reduced blood flow to the front part of the optic nerve. It can lead to vision loss, although the supplied reports do not establish that the medicines cause the condition in every patient.
The Korean warning covers tirzepatide, semaglutide, liraglutide and efpeglenatide products, including Mounjaro, Wegovy, Saxenda and Eflapegrastide product Eperzan. One suspected case of vision damage associated with NAION after use of a GLP-1 obesity medicine was reported domestically in December 2024. The ministry has requested safety information and plans to review whether product precautions should be changed.
